Cancer
Malignant Pancreatic Neoplasm
CI-CAN-00001159Explore in graph →
Top-level904 active trials8 approved drugs63 evidence items
- NCIt
- C9005
- ICD-10
- C25
- DOID
- 1793
- Other
- 1 more code
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00001159Explore in graph →
Clinical trials
3,630 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (516)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04928625 | A Trial of SHR-A1904 in Patients With Advanced Pancreatic Cancer | unknown | Phase 1 | 75 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 24, 2021 | clinicaltrials |
| NCT00597129 | Safety and Efficacy Study of 90Y-hPAM4 at Different Doses | completed | Phase 1 / Phase 2 | 21 | Gilead SciencesINDUSTRY | 1 | Aug 19, 2021 | clinicaltrials |
| A Study of Fractionated 90Y-hPAM4 Plus Gemcitabine in Pancreatic Cancer Patients Receiving at Least 2 Prior Therapies. |
| withdrawn |
| Phase 1 |
| 0 |
| Gilead SciencesINDUSTRY |
| 1 |
| Aug 19, 2021 |
| clinicaltrials |
| NCT02138383 | Enzalutamide in Combination With Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced Pancreatic Cancer | completed | Phase 1 | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 17, 2021 | clinicaltrials |
| NCT00603863 | Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer | completed | Phase 1 / Phase 2 | 80 | Gilead SciencesINDUSTRY | 1 | Aug 16, 2021 | clinicaltrials |
| NCT02305186 | Safety and Immunological Effect of Pembrolizumab in Resectable or Borderline Resectable Pancreatic Cancer(UVA-PC-PD101) | unknown | Phase 1 / Phase 2 | 68 | Craig L Slingluff, JrOTHER | 1 | Aug 13, 2021 | clinicaltrials |
| NCT01631552 | Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer | completed | Phase 1 / Phase 2 | 515 | Gilead SciencesINDUSTRY | 1 | Aug 12, 2021 | clinicaltrials |
| NCT02807844 | Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies | completed | Phase 1 / Phase 2 | 141 | Novartis PharmaceuticalsINDUSTRY | 11 | Aug 11, 2021 | clinicaltrials |
| NCT01465659 | Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery | completed | Phase 1 / Phase 2 | 29 | Northwestern UniversityOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT03316599 | Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer | completed | Phase 1 | 26 | Dana-Farber Cancer InstituteOTHER | 1 | Aug 3, 2021 | clinicaltrials |
| NCT02546531 | Defactinib Combined With Pembrolizumab and Gemcitabine in Patients With Advanced Cancer | completed | Phase 1 | 43 | Washington University School of MedicineOTHER | 1 | Jul 20, 2021 | clinicaltrials |
| NCT01335945 | Safety and Efficacy of Cryoablation for Abdominal Pain Associated With Pancreatic Cancer | terminated | Phase 1 | 14 | Boston Scientific CorporationINDUSTRY | 1 | Jul 16, 2021 | clinicaltrials |
| NCT02908451 | A Study of AbGn-107 in Patients With Gastric, Colorectal, Pancreatic or Biliary Cancer | terminated | Phase 1 | 39 | AbGenomics B.V Taiwan BranchINDUSTRY | 2 | Jul 13, 2021 | clinicaltrials |
| NCT03451773 | M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Jun 16, 2021 | clinicaltrials |
| NCT02368860 | OXIRI [Oxaliplatin (O), Xeloda (X) and Irinotecan (I)] in Pancreatic Adenocarcinoma(OXIRI) | completed | Phase 1 | 33 | National Cancer Centre, SingaporeOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04270929 | Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma(PANC-001) | withdrawn | Phase 1 | 0 | Roger Williams Medical CenterOTHER | 1 | Jun 1, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT02237157 | A Dose Escalation Safety Study of Locally-Delivered Gemcitabine in Pancreatic Cancer | completed | Phase 1 | 20 | RenovoRxINDUSTRY | 1 | May 7, 2021 | clinicaltrials |
| NCT02562898 | Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 18 | Margaret TemperoOTHER | 1 | May 6, 2021 | clinicaltrials |
| NCT03205176 | AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas | completed | Phase 1 | 49 | AstraZenecaINDUSTRY | 2 | May 6, 2021 | clinicaltrials |
| NCT01077986 | Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer | completed | Phase 1 / Phase 2 | 35 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02608229 | BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer | terminated | Phase 1 | 18 | Washington University School of MedicineOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT02311361 | Immune Checkpoint Inhibition (Tremelimumab and/or MEDI4736) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer | completed | Phase 1 / Phase 2 | 65 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2021 | clinicaltrials |
| NCT02048384 | A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer | completed | Phase 1 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Apr 12, 2021 | clinicaltrials |
| NCT02155088 | BYL719 in Combination With Gemcitabine and (Nab)-Paclitaxel in Locally Advanced and Metastatic Pancreatic Cancer | completed | Phase 1 | 15 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 8, 2021 | clinicaltrials |
| NCT02985801 | PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer | terminated | Phase 1 / Phase 2 | 16 | Massimo Raimondo, M.D.OTHER | 1 | Mar 15, 2021 | clinicaltrials |
| NCT02154737 | Gemcitabine and Pulse Dose Erlotinib in Second Line Treatment of Advanced Pancreatic Cancer | completed | Phase 1 | 24 | Tony Reid, M.D., Ph.D.OTHER | 1 | Mar 2, 2021 | clinicaltrials |
| NCT04764084 | Niraparib Combined With Anlotinib in Homologous Recombination Repair (HRR) Gene-mutated Advanced Solid Tumors | unknown | Phase 1 | 52 | Peking University Cancer Hospital & InstituteOTHER | 1 | Feb 21, 2021 | clinicaltrials |
| NCT03703063 | Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer | unknown | Phase 1 | 30 | Benaroya Research InstituteOTHER | 1 | Jan 27, 2021 | clinicaltrials |
| NCT02259114 | A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) | completed | Phase 1 | 47 | Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Jan 26, 2021 | clinicaltrials |
| NCT03760614 | A Study of Entinostat and FOLFOX in Subjects With Pancreatic Adenocarcinoma | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 0 | Jan 15, 2021 | clinicaltrials |
| NCT04707118 | Ntraperitoneal Thermal Perfusion Combined With Chemotherapy Versus Chemotherapy | unknown | Phase 1 | 106 | Fudan UniversityOTHER | 1 | Jan 13, 2021 | clinicaltrials |
| NCT04425876 | A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Resectable Pancreatic Cancer | unknown | Phase 1 | 74 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 31, 2020 | clinicaltrials |
| NCT03207724 | Study of Onivyde and 5-FU in Combination With Xilonix for Pancreatic Cancer With Cachexia(OnFX) | completed | Phase 1 | 16 | Andrew Hendifar, MDOTHER | 1 | Dec 30, 2020 | clinicaltrials |
| NCT03989310 | An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer | unknown | Phase 1 / Phase 2 | 50 | Chinese PLA General HospitalOTHER | 1 | Dec 23, 2020 | clinicaltrials |
| NCT01487785 | Dose-escalation, and Safety Study of LDE225 and Gemcitabine in Locally Advanced or Metastatic Pancreatic Cancer Patients | completed | Phase 1 | 18 | Novartis PharmaceuticalsINDUSTRY | 3 | Dec 19, 2020 | clinicaltrials |
| NCT01576666 | Phase Ib, Dose Escalation Study of Oral LDE225 in Combination With BKM120 in Patients With Advanced Solid Tumors | completed | Phase 1 | 120 | Novartis PharmaceuticalsINDUSTRY | 8 | Dec 19, 2020 | clinicaltrials |
| NCT01562899 | A Study of MEK162 and AMG 479 in Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 77 | PfizerINDUSTRY | 8 | Dec 10, 2020 | clinicaltrials |
| NCT03291938 | IACS-010759 in Advanced Cancers | completed | Phase 1 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03790423 | 18F-ASIS PET/CT Imaging of Tissue Factor Expression In Patients With Primary and Metastastic Cancer | completed | Phase 1 | 10 | Rigshospitalet, DenmarkOTHER | 1 | Nov 19, 2020 | clinicaltrials |
| NCT03180437 | Safety and Efficiency of IRE Plus γδ T Cell Against Locally Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 62 | Fuda Cancer Hospital, GuangzhouOTHER | 1 | Nov 2, 2020 | clinicaltrials |
| NCT02757391 | CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors | terminated | Phase 1 | 1 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 30, 2020 | clinicaltrials |
| NCT02045602 | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | completed | Phase 1 | 42 | Theriva Biologics SLINDUSTRY | 1 | Oct 8, 2020 | clinicaltrials |
| NCT02101580 | Ph 1B Trial With ADI-PEG 20 Plus Nab-Paclitaxel and Gemcitabine in Subjects With Pancreatic Cancer | completed | Phase 1 | 21 | Polaris GroupINDUSTRY | 1 | Oct 1, 2020 | clinicaltrials |
| NCT01385956 | SOM 230 and Gemcitabine in Advanced Pancreatic Cancer | completed | Phase 1 | 20 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 28, 2020 | clinicaltrials |
| NCT03925428 | Testing a New Anti-cancer Drug Combination, Entinostat and GSK525762C, for Advanced and Refractory Solid Tumors and Lymphomas | withdrawn | Phase 1 | 0 | National Cancer Institute (NCI)NIH | 0 | Sep 28, 2020 | clinicaltrials |
| NCT01189929 | A Study of Gemcitabine and Demcizumab (OMP-21M18) With or Without Abraxane® as 1st-line Treatment in Subjects With Locally Advanced or Metastatic Pancreatic Cancer | completed | Phase 1 | 57 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 3 | Sep 9, 2020 | clinicaltrials |
| NCT02005315 | A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 1 | 30 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT02050178 | Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer | completed | Phase 1 | 26 | OncoMed Pharmaceuticals, Inc.INDUSTRY | 1 | Sep 9, 2020 | clinicaltrials |
| NCT00769483 | MK-0646 and Gemcitabine +/- Erlotinib for Patients With Advanced Pancreatic Cancer | completed | Phase 1 / Phase 2 | 81 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 3, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Aug 24, 2021source: clinicaltrials